UK approval for Pfizer’s JAK inhibitor Cibinqo
Treatment approved for adults and adolescents with moderate to severe atopic dermatitis
Read More
Tag: atopic dermatitis
MHRA nod for AbbVie’s Rinvoq for adults and adolescents with eczema
Large-scale phase III study met all primary and secondary endpoints
Read More
Dupixent trial meets endpoints for childhood eczema
Sanofi/Regeneron biologic offers alternative to topical steroids
Read More
EU approval for Rinvoq to treat atopic dermatitis
Positive Phase III results for Abbvie’s oral JAK inhibitor
Read More
Lebrikizumab shows improvements in late-stage eczema trial
Endpoints of improved skin clearance, itch and quality of life were met
Read More
Patients gain early access to Pfizer’s atopic dermatitis drug
The MHRA has issued a positive scientific opinion for abrocitinib allowing its use via the early access to medicines scheme (EAMS)
Read More
Dupixent approved in EU for atopic dermatitis in children
First biologic to be approved for children aged six to 11 years with condition
Read More
Pfizer’s abrocitinib scores another phase III win in atopic dermatitis
JADE REGIMEN study investigated JAK1 inhibitor in moderate to severe atopic dermatitis
Read More
Lilly, Incyte tout new baricitinib data in eczema
Data presented at virtual European Academy of Dermatology and Venereology congress
Read More
AbbVie’s Rinvoq shows potential for atopic dermatitis
The selective and reversible JAK inhibitor hit all goals in the Phase III Measure Up study
Read More
EU regulators agree to review LEO’s dermatitis drug
The drug targets a key driver of the underlying inflammation in the condition
Read More
Sanofi unveils new data for Dupixent in children with dermatitis
Nearly three times as many children achieved clear or almost clear skin when treated with Dupixent and standard-of-care topical corticosteroids
Read More
